
Commentary|Videos|December 6, 2023
Dr Parsons on the Correlation Between Liquid Biopsy and HER2 Status in Breast Cancer
Author(s)Heather A. Parsons, MD, MPH
Heather A. Parsons, MD, MPH, discusses the correlation between liquid biopsy and HER2 status in breast cancer, according to data from a novel epigenomic platform.
Advertisement
Heather A. Parsons, MD, MPH, medical oncologist, Dana-Farber Cancer Institute, assistant professor, medicine, Harvard Medical School, discusses the correlation between liquid biopsy and HER2 status in breast cancer, according to data from a novel epigenomic platform.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
4
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
5




































